DoW Peer Reviewed Cancer, Clinical Trial Award
Defense Health Agency Contracting Activity - DHACA
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- May 6, 2026
- Amount
- Program total $45M
- Closes
- Oct 5, 2026 (in 17 days)
Similar opportunities open now
- DoW Peer Reviewed Medical, Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 4 days
- DoW, Peer Reviewed Cancer, Impact AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 17 days
- DoW Peer Reviewed Cancer, Idea AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 17 days
- DoW Ovarian Cancer, Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 13 days
- DoW Peer Reviewed Medical, Platform Clinical Translation AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 4 days
Classification and identifiers
- Solicitation number
- HT942526PRCRPCTA
- Assistance listing (CFDA)
- 12.420
Amount
Program total $45M
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applicatio...